John Frank an Industry Leader in Sleep and Respiratory Care Joins the Sommetrics Board of Directors
Sommetrics, a private company developing solutions to improve sleep health by providing innovative first in class products to treat sleep apnea, today announced that Mr. John Frank was elected to its Board of Directors. Mr. Frank has over three decades of experience and a successful track record of developing innovative solutions and world class organizations across ambulatory, home care and hospital segments.
Sommetrics Presents at 22nd Annual Needham Virtual Healthcare Conference
Sommetrics, a private company developing solutions to improve sleep health by providing innovative first in class products to treat sleep apnea, today announced that it made a presentation at the 22nd Annual Needham Virtual Healthcare Conference.
Sommetrics Presents Update on Pivotal SUPRA Sleep Apnea Trial at International Sleep and Breathing Conference
Sommetrics, a private company developing products and services to improve sleep health, today announced presentation of an interim update on its pivotal SUPRA study (Study Using Negative Pressure to Reduce Apnea) at the tri-annual, XVII International Symposium on Sleep and Breathing in Auckland, New Zealand.
Sommetrics Provides Update on the Pivotal SUPRA Clinical Trial for Sleep Apnea and Recent Corporate Accomplishments
VISTA, Calif. — April 20, 2022 — Sommetrics, a private company developing products and services to improve sleep health, today released an update on its key accomplishments during the first quarter of 2022.
Sommetrics Launches Pivotal Clinical Study of Its aerSleep II Product to Treat Sleep Apnea; Raises $11 Million in Series C Preferred Financing
VISTA, Calif. — September 29, 2021 — Sommetrics, a private company developing products and services to improve sleep health, today announced the launch of the pivotal clinical trial of its aerSleep® II device for the treatment of obstructive sleep apnea (OSA).
Sommetrics Receives IDE Approval From the FDA to Begin SUPRA Trial of aerSleep II for Treating Sleep Apnea
VISTA, Calif. — April 29, 2021 — Sommetrics is pleased to announce US Food and Drug Administration (FDA) approval of its Investigational Device Exemption (IDE) application to conduct a pivotal in-home clinical trial of its aerSleep II system.
Sommetrics Receives FDA Breakthrough Device Designation for Its aerSleep II Product to Treat Sleep Apnea
Sommetrics, a private company developing products and services to improve sleep health, today announced its lead sleep apnea product, aerSleep II, has received FDA Breakthrough Device designation. This program allows for additional FDA feedback to sponsors during the pre-marketing phase…
Sommetrics Receives ISO 13485:2016 Certification
Sommetrics, Inc., which provides products to treat airway obstruction during sleep and in acute care settings, announced today that its quality management system has been certified to the rigorous ISO 13485:2016 standard. During the audit process required for certification, Sommetrics was also evaluated and found to be in compliance…
Sommetrics and aerFree, LLC Contributing to Treatment of COVID-19
Sommetrics, Inc. a company providing products and services to improve sleep quality, and its partially owned affiliate, aerFree, LLC, which is dedicated to improving acute airway management, today announced the donation of their aerFree® product to leading academic centers to assist in the management of COVID-19 respiratory impairment.
Sommetrics Completes Study of New Sleep Apnea Treatment in Ethnic Japanese Subjects
Sommetrics, a company dedicated to developing state of the art products to treat obstructive sleep apnea (OSA), today announced the completion of clinical study SOM-014. This trial evaluated the safety, tolerability and effectiveness of the Sommetrics aerSleep™ product in ethnic Japanese subjects with obstructive sleep apnea (OSA).